Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2807/1560-7917.ES.2021.26.26.2100533 http://scihub22266oqcxt.onion/10.2807/1560-7917.ES.2021.26.26.2100533 34212840!8326661!34212840     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34212840&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Euro+Surveill 2021 ; 26 (26): ? Nephropedia Template TP {{tp|p=34212840|t=2021. Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021 |pdf=|usr=}}{{34212840}} gab.com Text Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021 JO: Euro Surveill http://www.kidney.de/pget.php?&tw=1&pmid=34212840 #FOAvip Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits. Twit Text FOAVip Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021 ????Euro Surveill http://www.kidney.de/pget.php?&tw=1&pmid=34212840 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34212840 #FOAvip English Wikipedia <ref>{{Cite pmid|34212840}}</ref> Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021 #MMPMID34212840 Tran Kiem C; Andronico A; Bosetti P; Paireau J; Alter L; Boelle PY; Fontanet A; Levy-Bruhl D; Cauchemez S Euro Surveill 2021[Jul]; 26 (26): ? PMID34212840show ga Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits. |*COVID-19[MESH] |*COVID-19 Vaccines[MESH] |France/epidemiology[MESH] |Humans[MESH] |Risk Assessment[MESH] |SARS-CoV-2[MESH]Benefits and risks associated with different uses of the COVID-19 vacc(epmc).pdf DeepDyve Pubget Overpricing